IL17A and inflammation: The anti-IL-33 mAb had no effect on these neutrophil-promoting cytokines at the early, 6 h, time point either, indicating that anti-IL-33 mitigates the type 2 or allergic inflammation, but has no effect on the IL-17 or IL-22 in RSV or OVA-RSV treated animals.